Tortoise Investment Management’s PROVECTUS BIOPHARMACEUTICALS, INC. (DE) PVCT Stock Holding History

Tortoise Investment Management’s Portfolio PVCT Stock Details PVCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-2,000	Closed	-$1K	–	443
2015 Q3	$1K	Hold	2,000	–	–	﹤0.01%	400
2015 Q2	$1K	Hold	2,000	–	–	﹤0.01%	425
2015 Q1	$2K	Hold	2,000	–	–	﹤0.01%	392
2014 Q4	$2K	Hold	2,000	–	–	﹤0.01%	439
2014 Q3	$2K	Hold	2,000	–	–	﹤0.01%	370
2014 Q2	$2K	Buy	+2,000	New	+$2.4K	﹤0.01%	391

Other funds holding PVCT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

HFBOT

Home Federal Bank of Tennessee Knoxville, Tennessee $463M AUM 24.62% 1-Year Est. Return

CCB

Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return

Tortoise Investment Management's PVCT Position: Q4 2015 in Review

Tortoise Investment Management sold out of PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) in Q4 2015, closing a stake of 2,000 shares — an estimated $1K sold.

Tortoise Investment Management first reported a position in PVCT in Q2 2014 and held it in 6 quarters. The position peaked at $2K in Q1 2015. 43 funds tracked by Wall St. Rank hold PVCT as of Q4 2015.

Tortoise Investment Management reported no remaining PROVECTUS BIOPHARMACEUTICALS, INC. (DE) position as of Q4 2015 after selling out during the quarter.
Tortoise Investment Management sold 2,000 PROVECTUS BIOPHARMACEUTICALS, INC. (DE) shares in Q4 2015, an estimated $1K.
Tortoise Investment Management first reported a position in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) in Q2 2014 and held it in 6 quarters.
Tortoise Investment Management's PROVECTUS BIOPHARMACEUTICALS, INC. (DE) position peaked at $2K in Q1 2015.
43 funds tracked by Wall St. Rank held PROVECTUS BIOPHARMACEUTICALS, INC. (DE) as of Q4 2015.

Based on Tortoise Investment Management's 13F filing for Q4 2015, filed 5 Feb 2016.